Johnson & Johnson (JNJ) is back in focus after the European Medicines Agency’s committee backed expanded use of its cancer drug Tecvayli with Darzalex, alongside a proposed US$1b Firefly Bio acquisition in oncology.

Recent oncology news has arrived on top of a strong run for Johnson & Johnson’s stock, with a 7 day share price return of 11.77% and a 30 day share price return of 14.73%. The 1 year total shareholder return of 73.47% and 5 year total shareholder return of 76.08% point to momentum that has been building rather than fading.

If Tecvayli and other oncology assets have caught your attention, it could be a good moment to see what else is gaining traction across healthcare AI by checking out the 41 healthcare AI stocks

With Johnson & Johnson now trading near its recent highs and sitting close to analyst targets, yet with an estimated 31% intrinsic discount, investors face a key question: is the stock still undervalued or is future growth already priced in?

Most Popular Narrative: 4.9% Overvalued

At a last close of $258.51 versus a fair value of $246.46 in the leading Johnson & Johnson narrative, valuation sits slightly ahead of that story.

Johnson & Johnson represents a high-quality, defensive healthcare leader with resilient earnings, strong cash flow generation, and disciplined capital allocation. Following the Kenvue spin-off, JNJ is now more focused on higher-margin Pharmaceutical and MedTech segments, improving long-term growth visibility.

Curious what supports that premium to fair value? The narrative leans on steady revenue compounding, firm margins and a future earnings base tied closely to oncology and MedTech strength.

Result: Fair Value of $246.46 (OVERVALUED)

However, investors still need to consider litigation exposure and potential setbacks in Johnson & Johnson’s oncology pipeline. These factors could challenge both earnings resilience and the current valuation narrative.

Another View: Johnson & Johnson Through a Cash Flow Lens

While the leading Johnson & Johnson narrative pins fair value at $246.46, our DCF model points in the opposite direction. On this view, JNJ at $258.51 trades below an estimated future cash flow value of $374.05. This frames the stock as undervalued rather than 4.9% overvalued. Which story feels more convincing to you: a premium on earnings today, or a discount on long term cash flows?

For investors who want to see how this cash flow result is built step by step, it can help to review the underlying assumptions and calculations in detail by going through the Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 42 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on Johnson & Johnson’s value and outlook can be useful, as long as you pressure test them against the data yourself and move quickly to shape your own view with the help of the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Johnson & Johnson?

If Johnson & Johnson has sharpened your focus on quality, it is worth widening your watchlist with other ideas that fit clear, data driven filters.

• Spot potential bargains early by reviewing companies trading on appealing valuations and solid fundamentals through the 42 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by focusing on companies with dependable payouts using the 9 dividend fortresses.
• Protect your capital first by zeroing in on companies flagged with lower risk profiles via the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.